Tetanus Toxoid Vaccine Market Report 2025

This Tetanus Toxoid Vaccine market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The tetanus toxoid vaccine market size has grown strongly in recent years. It will grow from $5.08 billion in 2024 to $5.46 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing awareness, rising incidence of tetanus cases, and government initiatives for immunization programs.

The tetanus toxoid vaccine market size is expected to see strong growth in the next few years. It will grow to $7.22 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing investments in research and development, and expanding distribution networks. Major trends in the forecast period include advancements in vaccine technology, emerging markets, launches of new products and services, and growing demand for vaccines.

The rising rates of preterm births are expected to drive the growth of the tetanus toxoid vaccine market in the coming years. Preterm birth refers to when a baby is born before completing 37 weeks of gestation, which can lead to various health complications due to incomplete development. The issue of preterm birth is influenced by factors such as increased maternal age, lifestyle choices, medical interventions like assisted reproductive technologies, maternal health conditions, and environmental influences. As preterm birth rates rise, there is an increased demand for tetanus toxoid vaccines, as more newborns and infants require immunization to protect against tetanus and other preventable diseases. For example, in December 2022, Tommy's, a UK-based organization focused on pregnancy and baby loss research, reported that the percentage of live preterm births in the United Kingdom rose from 7.5% in 2021 to 7.9% in 2022. Thus, the growing preterm birth rates are fueling the expansion of the tetanus toxoid vaccine market.

Leading companies in the tetanus toxoid vaccine market are focusing on developing advanced vaccines, such as the wP-IPV-based pentavalent vaccine, to meet increasing demand for comprehensive immunization solutions. The wP-IPV-based pentavalent vaccine combines multiple disease protections into a single injection, using inactivated bacteria and viruses to stimulate immunity without causing illness. For instance, Panacea Biotec Limited launched EasyFourPol in December 2023, a fully-liquid pentavalent vaccine that protects against Diphtheria, Tetanus, Pertussis, Polio, and Haemophilus Influenza Type B infections. This vaccine simplifies administration by eliminating the need for on-site preparation, ensuring efficient and effective immunization.

In January 2024, the Serum Institute of India Pvt. Ltd., an India-based vaccine manufacturing company, formed a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) network. The collaboration aims to speed up the development and production of affordable vaccines, strengthening global health security and ensuring equitable access during future disease outbreaks. The Coalition for Epidemic Preparedness Innovations is a Norway-based organization dedicated to advancing the development of vaccines.

Major companies operating in the tetanus toxoid vaccine market are Sanofi S.A., Novartis AG, LG Chem Ltd., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Astellas Pharma Inc., CSL Limited, Zoetis Inc., Meiji Holdings Company Ltd., Walvax Biotechnology, Shenzhen Kangtai Biological Products Co. Ltd., AJ Vaccines AS, PT Bio Farma, Serum Institute of India Pvt. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Amson Vaccines and Pharma Pvt Ltd., Incepta Vaccine Ltd., Mitsubishi Tanabe Pharma Corporation, BioNet-Asia Co. Ltd., Avalon Pharma Pvt. Ltd., Actiza Pharmaceutical Pvt. Ltd.

North America was the largest region in the tetanus toxoid vaccine market in 2024. The regions covered in the tetanus toxoid vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tetanus toxoid vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tetanus toxoid vaccine is designed to prevent tetanus, a severe bacterial infection caused by Clostridium tetani. It contains a form of the tetanus toxin, known as toxoid, which is harmless but prompts the immune system to generate antibodies against the toxin. These antibodies work by neutralizing the toxin produced by the bacteria, thereby providing protection against future infections.

The various types of tetanus toxoid vaccines are available. These include tetanus toxoid (Tt), diphtheria and tetanus (Dt), tetanus and diphtheria (Td), diphtheria, tetanus, and pertussis (Dtap), tetanus, diphtheria, and pertussis (Tdap), pentavalent, hexavalent, and others. Tetanus toxoid (Tt) vaccines consist of purified tetanus toxoid that stimulates the immune system to defend against tetanus-causing bacteria. These vaccines are used across different age groups, from pediatric to adult, in hospitals, clinics, government organizations, and other healthcare settings.

The tetanus toxoid vaccine market research report is one of a series of new reports that provides tetanus toxoid vaccine market statistics, including the tetanus toxoid vaccine industry global market size, regional shares, competitors with tetanus toxoid vaccine market share, detailed tetanus toxoid vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the tetanus toxoid vaccine industry. These tetanus toxoid vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tetanus toxoid vaccine market consists of sales of live, attenuated, inactivated, subunit, conjugate, and toxoid vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.